Geographic Atrophy - 37 Studies Found Completed : Evolution and Risk Factors Associated With Geographic Atrophy Progression : Geographic Atrophy : 2012-09-22 Terminated : A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD) : Geographic Atrophy : 2012-05-18 : Drug: Al-78898A 0.400 milligra Withdrawn : A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy : Geographic Atrophy : 2010-03-22 : Drug: RNA-144101 Intravitreous administration of RNA-144101 Active, not recruiting : Study of of APL-2 Therapy in Patients Geographic Atrophy : Geographic Atrophy : 2015-07-14 : Drug: APL-2 Other: Sham Procedure Terminated : Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy : Geographic Atrophy : 2012-08-28 : Drug: Sirolimus Immunosuppress Completed : Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) : Geographic Atrophy : 2013-01-31 : Drug: ORACEA® ORACEA® Active, not recruiting : CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) : Geographic Atrophy : 2015-08-03 : Drug: CLG561 Drug: LFG316 Completed : An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy : Geographic Atrophy : 2012-05-16 : Drug: Lampalizumab Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms. Active, not recruiting : A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy : Geographic Atrophy : 2014-11-07 : Other: Sham Sham injection wil Completed : A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy : Geographic Atrophy : 2009-09-08 : Drug: FCFD4514S Intravitreal escalating dose Next >>>
